Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Round Table Discussions
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Urology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Urology and
1 other channel

Expert Opinion / Commentary · January 21, 2015

Impact of Androgen Deprivation Therapy in Intermediate-Risk Prostate Cancer

Anthony D’Amico MD, PhD

 

 Save  Recommend
 Share

Additional Info

  1. Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 1.2014. J Natl Compr Canc Netw. 2013;11(12):1471-1479.
  2. Mitchell JA, Cooperberg MR, Elkin EP, et al. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol. 2005;173(4):1126-1131.
  3. Zumsteg ZS, Spratt DE, Pei I, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. 2013;64(6):895-902.
  4. Castle KO, Hoffman KE, Levy LB, et al. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys. 2013;85(3):693-699.
  5. Keane FK, Chen M-H, Zhang D, et al. The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer. 2014;120(12):1787-1793.
  6. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365(2):107-118.
  7. Pisansky TM, Hunt D, Gomella LG, et al. Duration of androgen suppression before radiotherapy for localized prostate cancer –Radiation Therapy Oncology Group Randomized Clinical Trial 9910 [published online December 22, 2014]. J Clin Oncol. doi: 10.1200/JCO.2014.58.0662.

  8. Zapatero A, Guerrero A, Maldonado, et al. Randomized phase 3 trial of adjuvant androgen deprivation in combination with high dose conformal radiation therapy in intermediate- and high-risk prostate cancer. Int J Radiat Oncol. 2014;90(1 Suppl):S1.

  9. Radiation Therapy Oncology Group. Radiation therapy with or without androgen-deprivation therapy in treating patients with prostate cancer. ClinicalTrials.gov Website. Available at: https://clinicaltrials.gov/ct2/show/NCT00936390. Updated July 21, 2014. Accessed January 4, 2015.

Further Reading

Recently Updated